Ansun Biopharma, Inc.
Quick facts
Phase 3 pipeline
- DAS181 · Infectious Disease; Virology
DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells. - DAS181 COVID-19 · Infectious Disease / Virology
DAS181 is a recombinant fusion protein that blocks SARS-CoV-2 entry into human cells by targeting the ACE2 receptor on the cell surface. - DAS181 OL · Infectious Disease / Virology
DAS181 is a recombinant fusion protein that blocks viral entry by presenting a soluble receptor domain that captures and neutralizes respiratory viruses.
Phase 2 pipeline
- DAS181 dry powder, formulation F02
- DAS181-F02 Dry Powder in Bulk · Respiratory
DAS181-F02 Dry Powder in Bulk is a fusion protein that targets the sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) receptor. - DAS181-F02 formulation
- DAS181-F04 formulation
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: